Some common potent oncogenic drivers, such as BRAF point mutations, do not always predict response to a relevant targeted agent across adult tumour types,2 but promising results in a variety of paediatric V600E mutated tumours (high- and low-grade glioma, papillary thyroid cancer, Langerhans cell histiocytosis, melanoma) raise the intriguing question of whether BRAF inhibitors may be tumour agnostic in children. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.